Health Care • Biotechnology: Pharmaceutical Preparations
$1.93 ▲ +0.05
(+2.66%)
MKT CAP: $3.6M • VOL: 31.2K
52W L $2 52W H $128
ROARABLE / RQD
E • 34/100
PIOTROSKI
1 / 9
MDCX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $96.2M | $31.3M | $13.2M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$34.4M | -$11.2M | -$4.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$47.3M | -$11.2M | -$5.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$22.8M | -$10.2M | -$4.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$22.8M | -$10.2M | -$4.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.7M | $4.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$67.6K | $3.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MDCX.